Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Droperidol
Drug ID BADD_D00731
Description A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593)
Indications and Usage Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
Marketing Status approved; vet_approved
ATC Code N05AD08
DrugBank ID DB00450
KEGG ID D00308
MeSH ID D004329
PubChem ID 3168
TTD Drug ID D03CJL
NDC Product Code 0143-9515; 64189-0601; 38779-0501; 0143-9514; 0517-9702
UNII O9U0F09D5X
Synonyms Droperidol | Inapsine | Dehidrobenzperidol | Dehydrobenzperidol | Droleptan
Chemical Information
Molecular Formula C22H22FN3O2
CAS Registry Number 548-73-2
SMILES C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.0120.000797%
Akathisia17.01.02.002; 19.06.02.006--
Altered state of consciousness19.07.01.003; 17.02.04.001--Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Autonomic nervous system imbalance24.06.01.005; 17.05.01.011; 08.01.01.010--Not Available
Blood pressure increased13.14.03.005--Not Available
Body temperature increased13.15.01.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.001--
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000131%Not Available
Chills15.05.03.016; 08.01.09.001--
Delayed recovery from anaesthesia12.02.20.005; 17.02.04.011--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.002417%Not Available
Dysphoria19.04.02.004--Not Available
Dyspnoea02.11.05.003; 22.02.01.0040.000196%
Dystonia17.01.03.0010.000287%Not Available
Electrocardiogram QT prolonged13.14.05.004--
Extrapyramidal disorder17.01.02.007--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gynaecomastia21.05.04.003; 05.05.02.003--
Hallucination19.10.04.003--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperprolactinaemia05.03.01.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene